Risultati per: Scoperto come far morire di fame le cellule tumorali

Circulation, Ahead of Print. BACKGROUND:Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI.METHODS:FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke.RESULTS:A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98–1.83];P=0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6–1.7];P=0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4–1.7];P=0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1–2.7];P=0.02).CONCLUSIONS:At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT02100722.

Da ricercatori italiani e americani. Utile anche contro i tumori

Annals of Internal Medicine, Volume 176, Issue 7, Page 1006, July 2023.

Sign on a realty office

Un brevetto Università Ca’ Foscari di Venezia e Cro di Aviano

Ricerca del team del National Cancer Centre di Singapore

Comunicato del 28/04/2023 n°20

Scoperta apre la strada a farmaci contro le neoplasie

Le donne nella prima meta’ della giornata, è il momento migliore

Con lo smog una ‘miscela esplosiva’ per il rischio ipertensione

Lo studio dei ricercatori dell’Ifom di Milano e del Cnr-Igm di Pavia, appena pubblicato su Nature Cell Biology, dimostra che il coronavirus viola i sistemi delle cellule, ne danneggia il Dna e impedisce di ripararlo

Lo studio dei ricercatori dell’Ifom di Milano e del Cnr-Igm di Pavia, appena pubblicato su Nature Cell Biology, dimostra che il coronavirus viola i sistemi delle cellule, ne danneggia il Dna e impedisce di ripararlo

This Medical News story discusses a study that found possible associations between postural orthostatic tachycardia syndrome (POTS) and COVID-19 vaccination and SARS-CoV-2 infection.

Inaugurato nei giorni dei primi lockdown (marzo 2020) poco fuori Amsterdam, ecco come vengono prodotti gli anti tumorali biologici nel grande stabilimento costato 135 milioni di euro